8-K Announcements
6Material company update
May 4, 2026·SEC
Material company update
Mar 13, 2026·SEC
Material company update
Mar 3, 2026·SEC
Evolus, Inc.(EOLS)Earnings, Financials & Key Ratios
EOLS•NASDAQ
$6.32
$416M mkt cap·Price updated May 6, 2026
AboutEvolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.Show more
- Revenue$297M+11.6%
- EBITDA-$29M-1.6%
- Net Income-$52M-2.4%
- EPS (Diluted)-0.80+1.2%
- Gross Margin64.86%-5.3%
- EBITDA Margin-9.71%+8.9%
- Operating Margin-12.65%+2.1%
- Net Margin-17.38%+8.2%
- ROIC-44.55%+21.0%
- Interest Coverage-1.91-15.3%
EOLS Key Insights
Evolus, Inc. (EOLS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y profit CAGR of 20.5%
- ✓Strong 5Y sales CAGR of 39.4%
- ✓Efficient asset utilization: 1.3x turnover
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
EOLS Price & Volume
Evolus, Inc. (EOLS) stock price & volume — 10-year historical chart
Loading chart...
EOLS Growth Metrics
Evolus, Inc. (EOLS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years39.36%
3 Years25.98%
TTM9.42%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM22.74%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM24.94%
Return on Capital
10 Years-51.75%
5 Years-32.02%
3 Years-27.28%
Last Year-23.49%
EOLS Recent Earnings
Evolus, Inc. (EOLS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (25%)●Beat Revenue 7/12 qtrs (58%)
Q2 2026Latest
May 4, 2026EPS
$0.10
Est $0.14
+28.6%
Revenue
$73M
Est $73M
+0.8%
Q2 2026
Mar 3, 2026EPS
$0.04
Est $0.06
-26.3%
Revenue
$90M
Est $90M
+0.9%
Q4 2025
Nov 5, 2025EPS
$0.14
Est $0.19
+26.3%
Revenue
$69M
Est $90M
-23.0%
Q3 2025
Aug 5, 2025EPS
$0.24
Est $0.09
-166.7%
Revenue
$69M
Est $85M
-18.7%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 4, 2026 | $0.10vs $0.14+28.6% | $73Mvs $73M+0.8% |
| Q2 2026 | Mar 3, 2026 | $0.04vs $0.06-26.3% | $90Mvs $90M+0.9% |
| Q4 2025 | Nov 5, 2025 | $0.14vs $0.19+26.3% | $69Mvs $90M-23.0% |
| Q3 2025 | Aug 5, 2025 | $0.24vs $0.09-166.7% | $69Mvs $85M-18.7% |
Based on last 12 quarters of dataView full earnings history →
EOLS Peer Comparison
Evolus, Inc. (EOLS) competitors in Therapy-focused branded biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ABBV | 362.56B | 204.98 | 86.49 | 8.57% | 6.91% | 62.15% | ||
 ACLX | 6.73B | 115.07 | -28.27 | -79.35% | -10.27% | -55.42% | 0.24 | |
 SKIN | 120.86M | 0.93 | -5.83 | -10.02% | -3.16% | -15.42% | 6.20 | |
 INMD | 861.05M | 13.59 | 9.50 | -6.16% | 25.33% | 14.52% | 0.02 | |
 AVAH | 1.43B | 6.76 | 6.44 | 20.19% | 9.25% | 9.53% | 6.91 | |
 MLAB | 585.38M | 105.96 | -294.32 | 11.47% | 1.51% | 2% | 1.14 | |
 IQV | 29.95B | 176.47 | 22.51 | 5.87% | 8.33% | 22.11% | 2.44 | |
 MCK | 91.09B | 743.67 | 28.91 | 16.22% | 1.09% |
Compare EOLS vs Peers
Evolus, Inc. (EOLS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
EOLS Income Statement
Evolus, Inc. (EOLS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 34.92M | 56.54M | 99.67M | 148.62M | 202.09M | 266.27M | 297.18M | 301.4M |
| Revenue Growth % | - | - | - | 61.89% | 76.29% | 49.1% | 35.98% | 31.76% | 11.61% | 9.42% |
| Cost of Goods Sold | 218K | 9K | 8.01M | 18.3M | 43.53M | 58.84M | 61.56M | 83.97M | 104.41M | 106.4M |
| COGS % of Revenue | - | - | 22.95% | 32.36% | 43.68% | 39.59% | 30.46% | 31.54% | 35.14% | - |
| Gross Profit | -218K▲ 0% | -9K▲ 95.9% | 26.91M▲ 299111.1% | 38.24M▲ 42.1% | 56.14M▲ 46.8% | 89.77M▲ 59.9% | 140.53M▲ 56.5% | 182.3M▲ 29.7% | 192.76M▲ 5.7% | 197.9M▲ 0% |
| Gross Margin % | - | - | 77.05% | 67.64% | 56.32% | 60.41% | 69.54% | 68.46% | 64.86% | 65.66% |
| Gross Profit Growth % | 33.13% | 95.87% | 299111.11% | 42.1% | 46.8% | 59.91% | 56.53% | 29.73% | 5.74% | - |
| Operating Expenses | 11.73M | 35.64M | 125.86M | 191.31M | 100.54M | 155.1M | 189.76M | 216.72M | 230.36M | 225.23M |
| OpEx % of Revenue | - | - | 360.37% | 338.36% | 100.87% | 104.37% | 93.9% | 81.39% | 77.52% | - |
| Selling, General & Admin | 4.82M | 29.15M | 113.59M | 98.19M | 112.07M | 141.84M | 164.94M | 198.03M | 220.79M | 216.13M |
| SG&A % of Revenue | - | - | 325.25% | 173.66% | 112.44% | 95.44% | 81.62% | 74.37% | 74.29% | - |
| Research & Development | 6.69M | 6.49M | 3.97M | 1.72M | 2.06M | 6.74M | 15.43M | 9.17M | 9.58M | 9.6M |
| R&D % of Revenue | - | - | 11.38% | 3.05% | 2.07% | 4.54% | 7.63% | 3.44% | 3.22% | - |
| Other Operating Expenses | -5K | 0 | 8.29M | 91.4M | -13.59M | 6.52M | 9.39M | 9.52M | 0 | 0 |
| Operating Income | -11.73M▲ 0% | -46.14M▼ 293.5% | -98.95M▼ 114.4% | -153.07M▼ 54.7% | -44.41M▲ 71.0% | -65.33M▼ 47.1% | -49.23M▲ 24.6% | -34.41M▲ 30.1% | -37.6M▼ 9.3% | -28.85M▲ 0% |
| Operating Margin % | - | - | -283.31% | -270.73% | -44.55% | -43.96% | -24.36% | -12.92% | -12.65% | -9.57% |
| Operating Income Growth % | 41.27% | -293.5% | -114.44% | -54.7% | 70.99% | -47.12% | 24.64% | 30.11% | -9.27% | - |
| EBITDA | -11.51M | -46.13M | -93.94M | -145.39M | -38.09M | -61.61M | -43.37M | -28.39M | -28.86M | -20.72M |
| EBITDA Margin % | - | - | -268.98% | -257.14% | -38.22% | -41.45% | -21.46% | -10.66% | -9.71% | -6.88% |
| EBITDA Growth % | 41.41% | -300.88% | -103.63% | -54.76% | 73.8% | -61.74% | 29.61% | 34.53% | -1.64% | 40.12% |
| D&A (Non-Cash Add-back) | 218K | 9K | 5M | 7.68M | 6.31M | 3.72M | 5.87M | 6.02M | 8.74M | 8.13M |
| EBIT | -11.73M | -45.94M | -97.11M | -152.43M | -45.37M | -57.58M | -47.68M | -31.02M | -37.6M | -21.65M |
| Net Interest Income | 0 | -660K | -6.11M | -9.87M | -1.4M | -8.98M | -12.97M | -15.47M | -17.76M | -14.06M |
| Interest Income | 0 | 203K | 1.84M | 635K | 1K | 119K | 860K | 3.26M | 1.93M | 1.51M |
| Interest Expense | 0 | 863K | 7.95M | 10.5M | 1.4M | 9.1M | 13.83M | 18.73M | 19.69M | 11.3M |
| Other Income/Expense | -5K | -660K | -6.11M | -9.87M | -2.36M | -8.99M | -12.28M | -15.35M | -13.36M | -13.71M |
| Pretax Income | -11.73M▲ 0% | -46.8M▼ 299.0% | -105.06M▼ 124.5% | -162.94M▼ 55.1% | -46.77M▲ 71.3% | -74.32M▼ 58.9% | -61.51M▲ 17.2% | -49.76M▲ 19.1% | -50.96M▼ 2.4% | -42.56M▲ 0% |
| Pretax Margin % | - | - | -300.82% | -288.18% | -46.92% | -50.01% | -30.44% | -18.69% | -17.15% | -14.12% |
| Income Tax | -7.25M | 65K | -15.03M | 77K | 42K | 95K | 176K | 664K | 677K | 349K |
| Effective Tax Rate % | 61.81% | -0.14% | 14.3% | -0.05% | -0.09% | -0.13% | -0.29% | -1.33% | -1.33% | -0.82% |
| Net Income | -4.48M▲ 0% | -46.87M▼ 946.1% | -90.03M▼ 92.1% | -163.01M▼ 81.1% | -46.81M▲ 71.3% | -74.41M▼ 59.0% | -61.69M▲ 17.1% | -50.42M▲ 18.3% | -51.64M▼ 2.4% | -43.42M▲ 0% |
| Net Margin % | - | - | -257.79% | -288.31% | -46.96% | -50.07% | -30.52% | -18.94% | -17.38% | -14.41% |
| Net Income Growth % | 77.67% | -946.14% | -92.11% | -81.06% | 71.28% | -58.97% | 17.1% | 18.26% | -2.42% | 22.74% |
| Net Income (Continuing) | -4.48M | -46.87M | -90.03M | -163.01M | -46.81M | -74.41M | -61.69M | -50.42M | -51.64M | -43.42M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.19▲ 0% | -1.92▼ 910.5% | -3.19▼ 66.1% | -4.83▼ 51.4% | -0.94▲ 80.5% | -1.33▼ 41.5% | -1.08▲ 18.8% | -0.81▲ 25.0% | -0.80▲ 1.2% | -0.67▲ 0% |
| EPS Growth % | 82.41% | -910.53% | -66.15% | -51.41% | 80.54% | -41.49% | 18.8% | 25% | 1.23% | 24.94% |
| EPS (Basic) | -0.19 | -1.92 | -3.19 | -4.83 | -0.94 | -1.33 | -1.08 | -0.81 | -0.80 | - |
| Diluted Shares Outstanding | 23.59M | 24.4M | 28.24M | 33.74M | 49.77M | 56.07M | 56.92M | 62.02M | 64.47M | 65.19M |
| Basic Shares Outstanding | 23.59M | 24.4M | 28.24M | 33.74M | 49.77M | 56.07M | 56.92M | 62.02M | 64.47M | 65.19M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
EOLS Balance Sheet
Evolus, Inc. (EOLS) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 72.82M | 94.34M | 152.2M | 127.61M | 178.8M | 100.8M | 112.42M | 151.34M | 142.92M | 138.92M |
| Cash & Short-Term Investments | 0 | 93.16M | 129.8M | 107.56M | 146.26M | 53.92M | 62.84M | 86.95M | 53.83M | 49.79M |
| Cash Only | 0 | 93.16M | 109.89M | 102.56M | 146.26M | 53.92M | 62.84M | 86.95M | 53.83M | 49.79M |
| Short-Term Investments | 0 | 0 | 19.91M | 5M | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 72.64M | 0 | 10.66M | 9.68M | 14.66M | 22.45M | 30.53M | 47.68M | 54.7M | 52.22M |
| Days Sales Outstanding | - | - | 111.42 | 62.49 | 53.67 | 55.13 | 55.14 | 65.36 | 67.18 | 62.08 |
| Inventory | 0 | 0 | 6.41M | 3.35M | 1.76M | 18.85M | 11M | 12.16M | 26.96M | 24.8M |
| Days Inventory Outstanding | - | - | 291.81 | 66.9 | 14.77 | 116.94 | 65.21 | 52.85 | 94.25 | 95.27 |
| Other Current Assets | 0 | 1.18M | 0 | 2.19M | 11.04M | 1.68M | 2.36M | 1.2M | 7.43M | 12.12M |
| Total Non-Current Assets | 79.41M | 77.5M | 88.25M | 81.46M | 78.68M | 77.18M | 76.58M | 81.23M | 82.95M | 81.72M |
| Property, Plant & Equipment | 0 | 0 | 4.97M | 4.71M | 4.09M | 4.56M | 7.85M | 10.41M | 0 | 0 |
| Fixed Asset Turnover | - | - | 7.03x | 12.00x | 24.35x | 32.57x | 25.74x | 25.59x | - | 50.07x |
| Goodwill | 21.21M | 21.21M | 21.21M | 21.21M | 21.21M | 21.21M | 21.21M | 21.21M | 21.21M | 21.21M |
| Intangible Assets | 56.08M | 56.08M | 59.64M | 55.3M | 50.63M | 48.6M | 47.11M | 48.75M | 48.04M | 46.74M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 2.13M | 221K | 2.43M | 240K | 2.76M | 2.81M | 409K | 858K | 13.7M | 30.86M |
| Total Assets | 152.23M▲ 0% | 171.84M▲ 12.9% | 240.44M▲ 39.9% | 209.07M▼ 13.0% | 257.48M▲ 23.2% | 177.98M▼ 30.9% | 189M▲ 6.2% | 232.57M▲ 23.1% | 225.87M▼ 2.9% | 220.65M▲ 0% |
| Asset Turnover | - | - | 0.15x | 0.27x | 0.39x | 0.84x | 1.07x | 1.14x | 1.32x | 1.35x |
| Asset Growth % | 96.44% | 12.88% | 39.92% | -13.05% | 23.16% | -30.88% | 6.19% | 23.05% | -2.88% | -6.21% |
| Total Current Liabilities | 212.75M | 5.28M | 24.44M | 180.25M | 57.66M | 46.51M | 48.29M | 62.96M | 75.31M | 68.02M |
| Accounts Payable | 445K | 1.56M | 5.8M | 9.62M | 6.09M | 8.94M | 4.27M | 9.24M | 23.36M | 0 |
| Days Payables Outstanding | 745.07 | 63.19K | 263.98 | 191.79 | 51.07 | 55.42 | 25.32 | 40.15 | 81.66 | 59.72 |
| Short-Term Debt | 211.33M | 0 | 0 | 93.45M | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 1.71M | 3.08M | 7.93M | 9.01M | 11.03M | 14.45M | 0 | 17.31M |
| Other Current Liabilities | 0 | 1.14M | 0 | 0 | 0 | 0 | 18.18M | 0 | 49.42M | 68.02M |
| Current Ratio | 0.34x | 17.88x | 6.23x | 0.71x | 3.10x | 2.17x | 2.33x | 2.40x | 1.90x | 1.90x |
| Quick Ratio | 0.34x | 17.88x | 5.97x | 0.69x | 3.07x | 1.76x | 2.10x | 2.21x | 1.54x | 1.54x |
| Cash Conversion Cycle | - | - | 139.25 | -62.39 | 17.38 | 116.65 | 95.03 | 78.06 | 79.78 | 97.64 |
| Total Non-Current Liabilities | 15.03M | 82.18M | 136.55M | 101.78M | 117.94M | 112.97M | 161.4M | 164.09M | 173.67M | 181.4M |
| Long-Term Debt | 0 | 16.9M | 91.45M | 40.51M | 71.22M | 71.88M | 120.36M | 121.51M | 146.1M | 156.41M |
| Capital Lease Obligations | 0 | 0 | 3.89M | 3.15M | 2.26M | 1.22M | 4.81M | 6.75M | 6.37M | 20.05M |
| Deferred Tax Liabilities | 14.99M | 15.05M | 0 | 25K | 40K | 22K | 27K | 6K | 28K | 49K |
| Other Non-Current Liabilities | 38K | 50.23M | 41.2M | 58.1M | 44.43M | 39.85M | 36.2M | 35.82M | 21.17M | 105.96M |
| Total Liabilities | 227.78M | 87.46M | 160.99M | 282.03M | 175.61M | 159.48M | 209.69M | 227.05M | 248.97M | 249.43M |
| Total Debt | 211.33M | 16.9M | 96.55M | 138.32M | 74.74M | 74.42M | 126.55M | 129.98M | 155M | 156.41M |
| Net Debt | 211.33M | -76.26M | -13.35M | 35.76M | -71.51M | 20.5M | 63.71M | 43.03M | 101.17M | 106.62M |
| Debt / Equity | - | - | 1.22x | - | 0.91x | 4.02x | - | 23.54x | - | -5.43x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -7.55x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -5.15x |
| Interest Coverage | - | -53.23x | -12.21x | -14.51x | -32.50x | -6.33x | -3.45x | -1.66x | -1.91x | -1.92x |
| Total Equity | -75.54M▲ 0% | -123.03M▼ 62.9% | 79.46M▲ 164.6% | -72.96M▼ 191.8% | 81.88M▲ 212.2% | 18.5M▼ 77.4% | -20.69M▼ 211.8% | 5.52M▲ 126.7% | -23.11M▼ 518.4% | -28.78M▲ 0% |
| Equity Growth % | -963.09% | -62.85% | 164.59% | -191.82% | 212.22% | -77.41% | -211.84% | 126.69% | -518.44% | -1639.1% |
| Book Value per Share | -3.20 | -5.04 | 2.81 | -2.16 | 1.64 | 0.33 | -0.36 | 0.09 | -0.36 | -0.44 |
| Total Shareholders' Equity | -75.54M | -123.03M | 79.46M | -72.96M | 81.88M | 18.5M | -20.69M | 5.52M | -23.11M | -28.78M |
| Common Stock | 0 | 1K | 1K | 1K | 1K | 1K | 1K | 1K | 1K | 1K |
| Retained Earnings | -75.54M | -123.03M | -213.06M | -376.07M | -422.88M | -497.29M | -558.98M | -609.4M | -661.04M | -671.71M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 6K | 0 | 0 | -337K | -427K | -905K | -156K | -278K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EOLS Cash Flow Statement
Evolus, Inc. (EOLS) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -13.04M | -25.67M | -93.38M | -57.87M | -33.39M | -84.91M | -34.01M | -18M | -42.27M | -42.27M |
| Operating CF Margin % | - | - | -267.38% | -102.35% | -33.5% | -57.14% | -16.83% | -6.76% | -14.22% | - |
| Operating CF Growth % | 1.75% | -96.91% | -263.83% | 38.03% | 42.31% | -154.32% | 59.95% | 47.07% | -134.82% | -236.41% |
| Net Income | -4.48M | -46.87M | -90.03M | -163.01M | -46.81M | -74.41M | -61.69M | -50.42M | -51.64M | -43.42M |
| Depreciation & Amortization | 218K | 9K | 5M | 7.68M | 6.31M | 4.5M | 5.87M | 6.02M | 8.74M | 7.02M |
| Stock-Based Compensation | 586K | 6.97M | 9.52M | 10.58M | 9.58M | 10.83M | 16.46M | 22.25M | 20.7M | 9.62M |
| Deferred Taxes | -7.25M | 65K | -15.05M | 25K | 15K | -18K | 5K | -21K | 21K | -6K |
| Other Non-Cash Items | 2.46M | 11.36M | 17.99M | 51.25M | 9.06M | 8.44M | 11.24M | 10.77M | 2.39M | 4.67M |
| Working Capital Changes | -2.11M | 2.79M | -20.81M | 35.6M | -11.54M | -34.25M | -5.89M | -6.6M | -22.48M | -14.34M |
| Change in Receivables | 0 | 0 | -11.05M | -1.08M | -5.57M | -9.39M | -9.52M | -19.6M | -11.51M | -10.69M |
| Change in Inventory | 0 | 0 | -4.48M | 4.54M | -2.98M | -10.69M | 4.19M | 3.25M | -11.12M | -15.17M |
| Change in Payables | -2.43M | 1.27M | 183K | 2.32M | -787K | 968K | -1.02M | 391K | 10.1M | 5.38M |
| Cash from Investing | 0 | -9K | -23.43M | 12.19M | 4.03M | -2.94M | -1.63M | -4.82M | -8.45M | -8.28M |
| Capital Expenditures | 0 | -9K | -4.57M | -3.14M | -393K | -1.62M | -473K | -1.47M | 0 | -955K |
| CapEx % of Revenue | - | - | 13.08% | 5.55% | 0.39% | 1.09% | 0.23% | 0.55% | 1.16% | - |
| Acquisitions | 0 | 0 | 4.22M | 2.32M | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | -4.22M | -2.32M | -577K | -1.32M | -1.15M | -3.35M | -8.45M | -7.33M |
| Cash from Financing | 13.04M | 118.84M | 133.55M | 38.35M | 73.05M | -4.15M | 44.64M | 47.41M | 17.34M | 26.59M |
| Debt Issued (Net) | 14.32M | 0 | 72.86M | 39.48M | -24.36M | 0 | 50M | 0 | -15K | -15K |
| Equity Issued (Net) | 0 | -239K | 73.31M | 0 | 103.34M | 0 | 0 | 51.21M | 1.16M | 404K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -1.29M | 119.08M | -12.63M | -1.13M | -5.92M | -4.15M | -5.36M | -3.8M | 16.19M | 26.2M |
| Net Change in Cash | 0▲ 0% | 93.16M▲ 0% | 16.73M▼ 82.0% | -7.33M▼ 143.8% | 43.69M▲ 696.1% | -92.33M▼ 311.3% | 8.92M▲ 109.7% | 24.11M▲ 170.5% | -33.13M▼ 237.4% | -18.1M▲ 0% |
| Free Cash Flow | -13.04M▲ 0% | -25.68M▼ 97.0% | -97.95M▼ 281.5% | -61.01M▲ 37.7% | -34.36M▲ 43.7% | -87.85M▼ 155.7% | -35.63M▲ 59.4% | -19.47M▲ 45.4% | -45.71M▼ 134.7% | -41.33M▲ 0% |
| FCF Margin % | - | - | -280.46% | -107.9% | -34.47% | -59.11% | -17.63% | -7.31% | -15.38% | -13.71% |
| FCF Growth % | 1.75% | -96.98% | -281.48% | 37.71% | 43.68% | -155.69% | 59.44% | 45.36% | -134.74% | -42.98% |
| FCF per Share | -0.55 | -1.05 | -3.47 | -1.81 | -0.69 | -1.57 | -0.63 | -0.31 | -0.71 | -0.71 |
| FCF Conversion (FCF/Net Income) | 2.91x | 0.55x | 1.04x | 0.36x | 0.71x | 1.14x | 0.55x | 0.36x | 0.82x | 0.95x |
| Interest Paid | 0 | 0 | 5.17M | 7.24M | 138K | 8M | 12.71M | 17.55M | 0 | 10.74M |
| Taxes Paid | 0 | 0 | 4K | 65K | 14K | 76K | 117K | 235K | 0 | 1.17M |
EOLS Key Ratios
Evolus, Inc. (EOLS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -113.31% | -5016.56% | -1049.79% | -148.27% | - | -913.08% | - | 174.92% |
| Return on Invested Capital (ROIC) | -9.33% | - | -112.25% | -794.25% | -321.37% | -198.52% | -90.04% | -56.37% | -44.55% | -44.55% |
| Gross Margin | - | - | 77.05% | 67.64% | 56.32% | 60.41% | 69.54% | 68.46% | 64.86% | 65.66% |
| Net Margin | - | - | -257.79% | -288.31% | -46.96% | -50.07% | -30.52% | -18.94% | -17.38% | -14.41% |
| Debt / Equity | - | - | 1.22x | - | 0.91x | 4.02x | - | 23.54x | - | -5.43x |
| Interest Coverage | - | -53.23x | -12.21x | -14.51x | -32.50x | -6.33x | -3.45x | -1.66x | -1.91x | -1.92x |
| FCF Conversion | 2.91x | 0.55x | 1.04x | 0.36x | 0.71x | 1.14x | 0.55x | 0.36x | 0.82x | 0.95x |
| Revenue Growth | - | - | - | 61.89% | 76.29% | 49.1% | 35.98% | 31.76% | 11.61% | 9.42% |
EOLS SEC Filings & Documents
Evolus, Inc. (EOLS) SEC filings — annual & quarterly reports (10-K, 10-Q)
EOLS Frequently Asked Questions
Evolus, Inc. (EOLS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Evolus, Inc. (EOLS) reported $301.4M in revenue for fiscal year 2025.
Evolus, Inc. (EOLS) grew revenue by 11.6% over the past year. This is steady growth.
Evolus, Inc. (EOLS) reported a net loss of $43.4M for fiscal year 2025.
Dividend & Returns
Evolus, Inc. (EOLS) had negative free cash flow of $41.3M in fiscal year 2025, likely due to heavy capital investments.
Explore More EOLS
Evolus, Inc. (EOLS) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates